[{"indications": "Indications\u00a0hyperlipidaemias of types IIa, IIb, III, IV and V in patients who\r\nhave not responded adequately to diet and other appropriate measures;\r\nprimary prevention of cardiovascular disease in men with hyperlipidaemias\r\nthat have not responded to diet and other appropriate measures; also\r\nsee notes above", "name": "GEMFIBROZIL", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.12 Lipid-regulating drugs", "Fibrates"], "cautions": "Cautions\u00a0lipid profile, blood counts, and liver-function tests\r\nbefore initiating long-term treatment; preferably avoid use with statins (high risk of rhabdomyolysis); correct hypothyroidism before initiating treatment (see Lipid-regulating Drugs); elderly; interactions: Appendix 1\r\n(fibrates)", "side-effects": "Side-effects\u00a0gastro-intestinal disturbances; headache, fatigue,\r\nvertigo; eczema, rash; less commonly atrial fibrillation; rarely pancreatitis, appendicitis, disturbances in liver\r\nfunction including hepatitis and cholestatic jaundice, dizziness,\r\nparaesthesia, sexual dysfunction, thrombocytopenia, anaemia, leucopenia,\r\neosinophilia, bone-marrow suppression, myalgia, myopathy, myasthenia,\r\nmyositis accompanied by increase in creatine kinase (discontinue if\r\nraised significantly), blurred vision, exfoliative dermatitis, alopecia,\r\nand photosensitivity)", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/2853.htm", "doses": ["1.2\u00a0g daily, usually in 2 divided doses; range 0.9\u20131.2\u00a0g\r\ndaily; child not recommended"], "pregnancy": "Pregnancy\u00a0manufacturers advise avoid\u2014embryotoxicity in animal studies"}]